Results 121 to 130 of about 243,619 (264)

A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy

BJU International, Volume 135, Issue 4, Page 648-656, April 2025.
Objective To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non‐coding RNA (lncRNA)‐based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer.
Joep J. de Jong, James A. Proudfoot, Siamak Daneshmand, Robert S. Svatek, Vikram Narayan, Ewan A. Gibb, Elai Davicioni, Shreyas Joshi, Aaron Dahmen, Roger Li, Brant A. Inman, Paras Shah, Iftach Chaplin, Jonathan Wright, Yair Lotan   +14 more
wiley   +1 more source

Squamous dedifferentiation and differentiated high-grade transformation of papillary thyroid carcinoma in metastatic lymph nodes: Two cases and literature review. [PDF]

Radiol Case Rep
Salih AM, Ali RM, Abdullah AM, Habibullah IJ, Hammood ZD, Abdulkarim MM, Qadir AA, Ahmed HA, Hassan SH, Kakamad FH.   +9 more
europepmc   +1 more source

Papillary Renal Neoplasm with Reversed Polarity in a 64-Year-Old Male: A Rare Case Report and Review of the Literature. [PDF]

Int Med Case Rep J
Wang Y, Zhang M, Su G, Zhou Q.
europepmc   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, EarlyView.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non‐muscle‐invasive bladder cancer

BJU International, EarlyView.
Objectives To evaluate whether longitudinal tumour‐informed circulating tumour DNA (ctDNA) testing identifies patients at increased risk of upstaging and recurrence in high‐risk non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods A cohort of 52 patients with high‐risk NMIBC underwent serial plasma ctDNA testing using a personalised tumour ...
Can Aydogdu, Betty Wang, Sean Thomas McSweeney, Gabriela Diaz, Taeris Guzman, Sahab Ram Dewala, Rakesh Arya, Mikayla Baer, Amanda Nizam, Christopher Wee, Shalini Moningi, Alberto Pieretti, Christopher J. Weight, Rebecca Campbell, Mohit Sindhani, Jihad Kaouk, Robert Abouassaly, Laura Bukavina   +17 more
wiley   +1 more source

A Case of Clear Cell Papillary Renal Cell Tumor: A Rare Entity With an Unusual Presentation. [PDF]

Clin Case Rep
Montazer M, Tayyebi Meibodi N, Soltani S, Beigi S.   +3 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma. [PDF]

Oncoscience
Rathod G, Parmar P.
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

The fascinating history of papillary thyroid carcinoma nuclei: revelation of two nuclear morphologies-"Classical papillary" and "papillary-like", with different pathobiologic characteristics. [PDF]

Cancer Cytopathol
Ohori NP, Minkowitz JM, Nikiforov YE, Seethala RR.   +3 more
europepmc   +1 more source